Medicenna Therapeutics Corp. SEC filings MDNAF

Medicenna Therapeutics Corp. has 178 filings in SEC EDGAR's recent list, going back to Mar 30, 2020. Its latest annual report, Form 20-F, was filed on Jun 27, 2023 for the period ended Mar 31, 2023. The most recent current report (Form 6-K) was filed on May 13, 2024. The company's fiscal year ends on March 31.

Medicenna Therapeutics Corp. SEC filings
Form Description Filed Period
D Filing Jul 6, 2026 —
15-12G Deregistration May 14, 2024 —
D Filing May 14, 2024 —
EFFECT Filing May 13, 2024 —
AW Form aw Apr 22, 2024 —
25-NSE Delisting notice Nov 20, 2023 —
EFFECT Filing Feb 27, 2023 —
CORRESP Letter to the SEC Feb 23, 2023 —
UPLOAD Letter from the SEC Feb 22, 2023 —
SUPPL Filing Aug 10, 2022 —
SUPPL Filing Aug 9, 2022 —
SUPPL Filing Aug 9, 2022 —
SUPPL Filing Dec 30, 2020 —
CERT Filing Aug 21, 2020 —
8-A12B Filing Aug 18, 2020 —
EFFECT Filing Jul 30, 2020 —
D/A Filing Apr 20, 2020 —
D Filing Mar 30, 2020 —

Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MDNAF (OTC)
Fiscal year ends
March 31
Incorporated in
Canada (Federal Level)
Headquarters
Toronto
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1807983

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.